U.S. markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.28
    +0.43 (+0.59%)
     
  • Gold

    1,778.70
    +1.30 (+0.07%)
     
  • Silver

    25.93
    +0.08 (+0.30%)
     
  • EUR/USD

    1.1930
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • GBP/USD

    1.3965
    +0.0017 (+0.12%)
     
  • USD/JPY

    110.9640
    +0.3290 (+0.30%)
     
  • BTC-USD

    33,116.12
    +686.56 (+2.12%)
     
  • CMC Crypto 200

    792.45
    -17.74 (-2.19%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Aldeyra Spikes 10% In Pre-Market On New Perceptive Stake

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares in Aldeyra Therapeutics (ALDX) are climbing 10% in Tuesday’s pre-market trading following a SEC filing showing that Joseph Edelman’s Perceptive Advisors now holds a 19.1% in the company.

According to the filing, Perceptive snapped up 3.2 million shares at an average price of $4.25 on Thursday, taking its indirect beneficial ownership to a total of 6,285,458 shares.

The New York-based hedge fund firm has $5 billion under management, and was founded by Edelman in 1999 to focus on investing in biotech stocks. Edelman now has a net worth of $1.2 billion.

Shares in Aldeyra are down 11% year-to-date, but analysts have a bullish Strong Buy consensus on the stock with 4 recent buy ratings. The average analyst price target stands at $27 (470% upside potential). (See ALDX stock analysis on TipRanks)

On July 7, Aldeyra announced development plans for dry eye disease, which will include two pivotal studies focused on investigating RASP as an objective-sign endpoint for dry eye disease (DED).

Reproxalap, the company’s lead clinical candidate, is a novel small molecule RASP inhibitor that covalently binds free aldehydes and diminishes excessive RASP levels.

“In addition to an increased likelihood of FDA approval, the development path could be expedited from the ability to demonstrate RASP in potentially smaller and shorter studies” commented Oppenheimer’s Justin Kim following the announcement.

He is now seeing with greater clarity reproxalap’s potential to be on the market in 2022 and the shift in emphasis on catalysts for the stock as it approaches a potential first commercialization. “Ahead of a richer and now nearer-term catalyst setup, we stay bullish” the analyst concluded. He reiterated a buy rating on the stock and $15 price target (219% upside potential).

Related News:
Equillium Explodes 260% On Positive Covid-19 Results; India Approval
Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk
Moderna Inks Deal With Rovi To Supply Potential Covid-19 Vaccine Outside US

More recent articles from Smarter Analyst: